Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

DNA vectors have been widely used as a priming of poxvirus vaccine in prime/boost regimens. Whether the number of DNA impacts qualitatively or quantitatively the immune response is not fully explored. With the aim to reinforce T-cell responses by optimizing the prime-boost regimen, the multicentric...

Descripción completa

Detalles Bibliográficos
Autores principales: Lévy, Yves, Lacabaratz, Christine, Ellefsen-Lavoie, Kim, Stöhr, Wolfgang, Lelièvre, Jean-Daniel, Bart, Pierre-Alexandre, Launay, Odile, Weber, Jonathan, Salzberger, Bernd, Wiedemann, Aurélie, Surenaud, Mathieu, Koelle, David M., Wolf, Hans, Wagner, Ralf, Rieux, Véronique, Montefiori, David C., Yates, Nicole L., Tomaras, Georgia D., Gottardo, Raphael, Mayer, Bryan, Ding, Song, Thiébaut, Rodolphe, McCormack, Sheena, Chêne, Geneviève, Pantaleo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319597/
https://www.ncbi.nlm.nih.gov/pubmed/32589686
http://dx.doi.org/10.1371/journal.ppat.1008522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319597/
https://www.ncbi.nlm.nih.gov/pubmed/32589686
http://dx.doi.org/10.1371/journal.ppat.1008522

Ejemplares similares